Gains from no real PAINS: Where ‘Fair Trial Strategy’ stands in the development of multi-target ligands

Compounds that selectively modulate multiple targets can provide clinical benefits and are an alternative to traditional highly selective agents for unique targets. High-throughput screening (HTS) for multitarget-directed ligands (MTDLs) using approved drugs, and fragment-based drug design has becom...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Jianbo, Zhong, Hui, Wang, Kun, Li, Na, Chen, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642439/
https://www.ncbi.nlm.nih.gov/pubmed/34900527
http://dx.doi.org/10.1016/j.apsb.2021.02.023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642439/
https://www.ncbi.nlm.nih.gov/pubmed/34900527
http://dx.doi.org/10.1016/j.apsb.2021.02.023

Ejemplares similares